NICE guidance for access to advanced breast cancer treatment

NICE has published draft guidance today recommending trastuzumab deruxtecan for use in the Cancer Drugs Fund (CDF) as an option for treating HER-positive unresectable or metastatic breast cancer in adults, after two or more anti-HER2 therapies.

The decision means it will be the first time trastuzumab deruxtecan (also called Enhertu) has been commissioned for use in any European country. Up to 400 people will have immediate access to the treatment while more data is collected showing how much longer people who are taking it live, compared with people taking chemotherapy.

There is currently a lack of clinical trial data directly comparing trastuzumab deruxtecan with chemotherapy. However, the committee concluded that data from ongoing trials of trastuzumab deruxtecan and from NHS practice would help address the uncertainty about clinical effectiveness. Trastuzumab deruxtecan is therefore recommended for use in the Cancer Drugs Fund.

Current treatment for HER2‑positive unresectable or metastatic breast cancer includes anti‑HER2 therapies. After two or more anti‑HER2 therapies, the standard care is chemotherapy (such as capecitabine, vinorelbine or eribulin).

Meindert Boysen, Deputy Chief Executive and Director of the Centre for Health Technology Evaluation at NICE, said: “Unfortunately there is no cure for breast cancer that has spread to other parts of the body or that can’t be removed surgically.

The committee heard from patient experts who explained that, because of its side effects, people want to avoid having chemotherapies for as long as possible.

“Trastuzumab deruxtecan is a promising new treatment that has the potential to increase the length of time before the disease gets worse and how long people live overall.

"We’re therefore pleased that our work has allowed a deal to be struck between the company and NHS England supporting access to trastuzumab deruxtecan as an option in the CDF for people with this type of breast cancer.”

NHE Sept/Oct 21

NHE Sept/Oct 21

Improving care for long-term conditions

Join us in our September/October edition of National Health Executive, as we explore a range of topics impacting and improving the care that we can deliver to patients, the facilities within which we deliver them, and the opportunities in the digital space to accent and evolve our care capabilities


View all videos
National Health Executive Presents

National Health Executive Presents

NHE365 Virtual Festival: Digital Healthcare

The integration of new technology, such as using virtual outpatient appointments instead of face-to-face reviews of patients in the hospital. Adapting the ways in which our NHS workers serve people has been critical in continuing to provide high-quality treatment, a positive patient experience and preventing Covid-19 transmission during the pandemic. Our healthcare sector has the potential to transform the way we continue to provide essential services while also improving patient care. But how easy is the integration of these innovations into routine NHS practice?

On the 28th of October, at the NHE365 Virtual Hospitals & Technology Enabled Care online event, we will be discussing patient flow and experience, reducing waiting times, reducing the patient backlog and increasing technology adoption. Will you be attending? 

Finger on the Pulse

Ep 14. Health messaging is a science, Professor Craig Jackson

On Episode 14 of NHE's Finger on the Pulse podcast, we're joined by Professor Craig Jackson, Professor of Occupational Health Psychology
Birmingham City University to discuss the coronavirus pandemic, the health messaging around it and how those in power have missed a trick by overlooking the key role of psychology in informing the public of restrictions, measures and the ever-changing situation

More articles...

View all